A double-blind crossover pilot study of l-deprenyl (selegiline) combined with cholinesterase inhibitor in Alzheimer's disease.
The potential efficacy of oral l-deprenyl (5 mg b.i.d.) added to the regimen of 10 patients with Alzheimer's disease receiving either tacrine or physostigmine was assessed in a double-blind, placebo-controlled, 4-week, two-period crossover pilot study. l-Deprenyl was associated with significant improvement in scores on the cognitive subscale of the Alzheimer's Disease Assessment Scale, suggesting possible additive effects of l-deprenyl to the effects of cholinesterase inhibitors.
Schneider
L S
LS
Department of Psychiatry, University of Southern California School of Medicine, Los Angeles.
Olin
J T
JT
Pawluczyk
S
S
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010830:Physostigmine / Q000627:therapeutic use*; D010865:Pilot Projects; D011569:Psychiatric Status Rating Scales; D012642:Selegiline / Q000627:therapeutic use*; D013619:Tacrine / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D012642:Selegiline; D013619:Tacrine; D010830:Physostigmine